Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05654948
Other study ID # DR220190-MINDDE
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 9, 2023
Est. completion date August 2024

Study information

Verified date October 2023
Source University Hospital, Tours
Contact Wissam EL HAGE
Phone 0247476529
Email wissam.elhage@univ-tours.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators will include patients suffering from Major Depressive Disorder (MDD), in episode. The patients will undertake neuropsychological tasks evaluating executive function and clinical assessment related to depressive symptoms, anxiety, transdiagnostic symptoms and psychological skills.


Description:

The investigators will include patients suffering from MDD, in episode. The patients will be evaluated with the MINI-7 interview. Then, the participants will undertake different neuropsychological tasks evaluating executive function: the stroop task, the D2 tasks, the finger tapping test and the mindpulse. The participants will also undertake clinical evaluation the MADRS, the Transdiagnostic Skills Scale, the Symptomatic Transdiagnostic Test, the STAI and the Severity Insomnia Indexes. The investigators will perform correlational analysis between the neuropsychological tasks and the clinical evaluations. The investigators will also compare the predictive power of the different neuropsychological tasks on depressive symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date August 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age between 18 and 65 years. - Diagnosis of a depressive episode according to DSM-5 criteria, confirmed by the Mini International Neuropsychiatric Interview (MINI 7.0 according to DSM-5). - No evidence of bipolar disorder or schizophrenia, confirmed by the MINI. - No dementing neurological disease. - No guardianship or trusteeship Exclusion Criteria: - Opposition to data processing - Depressive episode in the context of a known bipolar disorder or schizophrenic illness

Study Design


Related Conditions & MeSH terms


Intervention

Other:
computerised cognitive performance test : MindPulse
In practice, this tool measures the speed at which an individual reacts to the appearance of a simple image on a screen with instructions to react only to certain images. It thus makes it possible to measure the speed of information processing, attention, executive functions and reaction to difficulty

Locations

Country Name City State
France Clinique psychiatrique universitaire Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary MADRS score The severity of the depression will be assessed using the MADRS score. Montgomery-Asberg Depression Scale (MADRS) The scale has 10 items rated from 0 to 6.
0 to 6 points: the patient is considered healthy. 7 to 19 points: the patient is considered to be in mild depression. 20 to 34 points: the patient is considered to be in moderate depression. > 34 points: the patient is considered to be in severe depression.
baseline
Primary Simple reaction time (SRT) obtained at the MindPulse test The "simple reaction time" (SRT) is the reaction time to the first test (the subject releases the mouse click as quickly as possible when an image appears) , it contains the time needed to perceive and analyse the image, to formulate the response and to execute the motor response. Baseline
Primary Go/NoGo score obtained at the MindPulse test reaction time with a categorisation where the subject must react or not react (Go/NoGo) according to the categorical target, in this case a light or dark colour (white coloured image or grey coloured image). Baseline
Primary Executive speed (ES) obtained at the MindPulse test The ES Score corresponds to the Executive Speed, i.e. the average time of categorisation of the subject. Baseline
Primary Reaction to difficulty obtained at the MindPulse test It corresponds to the adaptation of the subject to the level of difficulty. The shift of the circle above the blue rectangle indicates a higher than expected slowing down in reaction to the difficulty of the instruction, while a shift below the blue rectangle indicates that the participant is not slowing down enough in response to the difficulty and is at risk of making mistakes. Baseline
Secondary Level of anxiety measured by a self-questionnaire : State Trait Anxiety Inventory (STAI) 40 items rated from 1 to 4 Baseline
Secondary clinical characterisation Measured by a scale : Transdiagnostic Skills Scale (T2S) 42 items rated from 1 to 7 Baseline
Secondary clinical characterisation Measured by a questionnaire : Transdiagnostic Evaluation Scale (ETE) 66 items rated from 1 to 7 Baseline
Secondary insomnia severity Measured by an insomnia severity index (ISI) 5 items rated from 0 to 4 Baseline
Secondary Stroop test standardised cognitive assessment is measured by neuropsycological tests as stroop test Baseline
Secondary D2R standardised cognitive assessment is measured by neuropsycological tests as D2R test that measures the concentration Baseline
Secondary Finger tapping test standardised cognitive assessment is measured by neuropsycological tests as Finger tapping test rated from 0 to 4 Baseline
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Recruiting NCT05708222 - Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
Completed NCT01879111 - Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback N/A
Unknown status NCT01212848 - Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation Phase 3
Not yet recruiting NCT05547711 - Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT03288714 - Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder N/A
Completed NCT03899168 - Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Recruiting NCT05910775 - Role Of Non-Specific Effects in The Treatment of Depression With Esketamine N/A
Terminated NCT04383509 - Electroconvulsive Treatment Followed by Cognitive Control Training N/A
Completed NCT05683028 - RCT for Electroconvulsive Treatment Followed by Cognitive Control Training N/A
Enrolling by invitation NCT05701345 - Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder N/A
Recruiting NCT04123301 - Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics. N/A
Completed NCT05686408 - Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT03543410 - A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression Phase 2
Completed NCT04953338 - Mental Health Associations With Vitiligo
Recruiting NCT06152705 - Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression N/A